Brunettes bag the billionaires, blondes get the barmen

These frequencies probably just reflect the frequencies of the different hair colours in the respective populations. And with hair colour very changeable and changing, it is in any case hard to know what is being surveyed here

It's official, if you're a brunette like Carla Bruni, you're more likely to marry a successful man than your blonde counterparts. Experts at LOVE@LYCOS the dating channel of Lycos.co.uk analysed the WAG's hair colour of the world's top 100 billionaires to determine if there is a predominant hair colour wealthy men seen to go for. The majority by a long way were brunettes, with 62% of billionaires marrying women with brown hair.

The results went on to show that fair haired ladies come in a poor second with only 22% of the world's top billionaires marrying blondes. Women with black hair lag behind in third place, enticing on 16% of the world's wealthiest, whilst carrot-tops come in last.

Source






Drug to fight aggressive breast cancer now subsidized in Australia

The breast cancer treatment, Tykerb, has been placed on the the Pharmaceutical Benefits Scheme (PBS), making it cheaper for women affected by an aggressive form of the disease. Federal Health Minister Nicola Roxon announced today that from May 1, Lapatinib, known commercially as Tykerb, would be subsidised under the scheme's arrangements. Tykerb had been found to slow the progress of and improve symptoms associated with advanced HER-2 positive breast cancer, Ms Roxon said. "Without any subsidy, the medicine would cost women between $3500 and $4000 each month," she said. "Lapatinib will be available to people with HER-2 positive metastatic or advanced breast cancer for whom other treatments have proved ineffective."

The drug is used in treating a particularly aggressive form of disease known as advanced HER-2 positive breast cancer. "HER-2 positive breast cancer is an aggressive form of cancer that particularly impacts upon younger women," Ms Roxon said. "Around 87 per cent of patients diagnosed with advanced breast cancer will die from the disease within five years. "About 2000 Australians are diagnosed with HER-2 positive breast cancer each year. "HER-2 positive breast cancer is one that has spread to distant parts of the body (metastasised) or which cannot be removed with surgery."

Ms Roxon said breast cancer was the most common cancer in women and affected 14,000 Australians per year. In 2004, more than 2600 people died from the disease in Australia.

An international study released in 2006 found that Tykerb and the chemotherapy drug Xeloda in combination were effective in women who had failed to react to Herceptin. The combination slowed down the disease's progression compared to chemotherapy alone and reduced the risk of the cancer spreading to the brain. The therapy has already been approved for use in the US and overseas analysts have predicted that Tykerb could eventually record annual global sales of about $A4.5 billion.

Source